{"count":2329,"next":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1880&ordering=begin_planned","previous":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1840&ordering=begin_planned","results":[{"id":7916,"title":{"de":"ARCTECH: Das Potenzial von Archaea nutzbar machen\r\nAusbildung der nächsten Visionäre Europas für eine innovative und nachhaltige Zukunft","en":"ARCTECH: Harnessing the potential of Archaea\r\nTraining Europe’s next visionaries for an innovative and sustainable future"},"short":"ARCTECH","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2024-03-01T01:00:00+01:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2028-02-29T01:00:00+01:00","assignment":"2023-12-07T10:05:45+01:00","program":209,"subprogram":"HORIZON-MSCA-2022-DN-01","organization":14023,"category":10,"type":10,"partner_function":2,"manager":90021,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":"101120407","ethics_committee":null,"edudract_number":null,"persons":["7916-90021-10","7916-99612-12","7916-100035-12","7916-104024-12","7916-109121-12","7916-100806-12","7916-106195-12","7916-128134-12"]},{"id":7529,"title":{"de":"Impfbare Krankheiten bei schwangeren und stillenden Frauen","en":"Vaccine preventable diseases in pregnant and lactating women"},"short":null,"url":null,"abstract":{"de":"Given its effectiveness in protecting pregnant women, foetuses and infants from infectious diseases, maternal immunization has gained interest in recent years. Nevertheless, information on the optimal timing for this vaccination strategy is limited by the relatively poor understanding of the immunobiology of vaccine responses in pregnancy and during lactation. Dynamic changes in immune function occur during gestation that may affect vaccine response in pregnant women if vaccination is given at a different timepoint in pregnancy. Additionally, since several recommendations for vaccination in pregnancy or during lactation are currently in place or being made, the question arises whether the administration of different vaccines has an impact on the induction of the antibody-mediated immune responses and whether this possibly also influence the kinetics of these vaccine-induced antibodies. This implies that repeated sampling after vaccination is needed to describe and analyse antibody kinetics. However, the design of maternal immunization studies is typically informed by generic statistical approaches not dealing with questions as to when and how often samples should be taken in order to gather the right amount of information to investigate antibody kinetics.\r\n\r\nThe objectives are 1) to describe and compare kinetics of antibodies to two different vaccines (Tdap, COVID-19) and to investigate potential interactions; 2) to develop a framework to plan maternal immunization studies.\r\n\r\nIn two ongoing trials, serum and breastmilk samples are collected at several timepoints during and after pregnancy. In the Tdap trial, three cohorts of women are included differing in gestational age at which women are vaccinated with Tdap vaccine. In the COVID-19 trial, the effects of vaccinating pregnant and lactating women with a COVID-19 vaccine are investigated. In this project, we will measure antibody titres in blood and breastmilk samples for the vaccine not being the focus of the respective trial, i.e. getting in all samples information on Tdap and COVID-19. We will use mathematical models combined with statistical tools to analyse dynamic immune response and to improve the design of maternal immunization studies.\r\n\r\nThe main innovations are:1) comparing kinetic behaviour of antibodies induced by two different vaccines on several time points in serum and breastmilk; 2) investigating potential interactions of antibodies induced by two vaccines impacting the kinetics over time; 3) development of novel methodology to analyse and plan maternal immunization studies. Within this project, we focus on pertussis and COVID-19 as examples, but outcomes of this project can be applied to other infectious diseases for which vaccines can be administered in pregnancy or during lactation.","en":"Aufgrund der hohen Anfälligkeit von Schwangeren, Föten und Säuglingen für Infektionskrankheiten hat die Immunisierung von Müttern in den letzten Jahren an Interesse gewonnen. Dennoch ist der optimale Zeitpunkt für eine Impfung in der Schwangerschaft noch immer unbekannt. Außerdem kommt es während der Schwangerschaft zu dynamischen Veränderungen der Immunfunktion, wenn ein Impfstoff zu einem anderen Schwangerschaftsalter verabreicht wird. Dies kann die Reaktion auf den Impfstoff und die Kinetik der durch den Impfstoff induzierten mütterlichen Antikörper im Blut und in der Muttermilch der Schwangeren beeinflussen.\r\n\r\nDa derzeit mehrere Empfehlungen für Impfungen in der Schwangerschaft gelten bzw. ausgesprochen werden, stellt sich außerdem die Frage, ob die Verabreichung verschiedener Impfstoffe in der Schwangerschaft Auswirkungen auf die Immunreaktionen auf diese Impfstoffe hat und möglicherweise eine Wechselwirkung in der Kinetik der durch verschiedene Impfstoffe induzierten Antikörper verursacht.\r\n\r\nIm Rahmen dieses Projekts wollen wir den optimalen Zeitpunkt für die Impfung in der Schwangerschaft bestimmen, die Antikörperkinetik vergleichen und mögliche Wechselwirkungen bei der Immunantwort untersuchen, wenn verschiedene Impfstoffe (z. B. Pertussis, COVID-19) in der Schwangerschaft verabreicht werden. Wir entwickeln konzeptionelle Rahmen, in denen wir statistische Ansätze mit mathematischen Modellen von Infektionskrankheiten kombinieren, um die Analyse und das Design von Studien zur mütterlichen Immunisierung zu verbessern.\r\n\r\nDer Schwerpunkt des Projekts liegt auf Pertussis und COVID-19, aber die Ergebnisse können auch auf andere Infektionskrankheiten angewendet werden, gegen die Impfstoffe in der Schwangerschaft verabreicht werden können."},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-06-01T02:00:00+02:00","end_planned":"2027-12-31T01:00:00+01:00","end_effective":"2028-05-31T02:00:00+02:00","assignment":"2023-04-27T14:12:52+02:00","program":111,"subprogram":null,"organization":14026,"category":10,"type":10,"partner_function":1,"manager":83644,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"I6376","ethics_committee":null,"edudract_number":null,"persons":["7529-83644-10"]},{"id":7278,"title":{"de":"CDK9 Inhibition bei RAS-mutierter CMML","en":"CDK9 inhibition in RAS-mutated CMML"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-03-01T01:00:00+01:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2027-06-30T02:00:00+02:00","assignment":"2022-12-01T10:38:07+01:00","program":72,"subprogram":null,"organization":14082,"category":10,"type":10,"partner_function":4,"manager":57402,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P36672","ethics_committee":null,"edudract_number":null,"persons":["7278-57402-10","7278-97430-12","7278-122511-12"]},{"id":7252,"title":{"de":"Integration von Bewegung und NAD+ zur Verringerung des kardiometabolischen Risikos","en":"Integrating exercise and NAD+ to reduce cardiometabolic risk"},"short":"INTERACD+ BioTechMed Flagship 2022","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-03-01T01:00:00+01:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2027-02-28T01:00:00+01:00","assignment":"2022-11-16T10:02:31+01:00","program":null,"subprogram":null,"organization":14083,"category":10,"type":10,"partner_function":3,"manager":60041,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[2325],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7252-60041-10","7252-75758-12","7252-94512-12","7252-108473-12","7252-119109-12","7252-122750-12"]},{"id":7622,"title":{"de":"EVI 2.0 - Evidenzbasierte Informationen zur Unterstützung von gesundheitskompetenten Entscheidungen","en":"EVI 2.0 - Evidence-based health information to increase health literacy"},"short":"EVI 2.0","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2024-12-31T01:00:00+01:00","end_effective":"2024-12-31T01:00:00+01:00","assignment":"2023-06-19T11:56:03+02:00","program":null,"subprogram":null,"organization":27964,"category":10,"type":10,"partner_function":4,"manager":51117,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[2160],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7622-51117-10"]},{"id":7595,"title":{"de":"ELPHI: Bioelektronische Implantate für steuerbare Chemoimmunotherapie","en":"ELPHI: Bioelectronic Implants for Tunable Chemoimmunotherapy"},"short":"Chemoimmuno ELPHI ","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2026-12-31T01:00:00+01:00","end_effective":"2027-12-31T01:00:00+01:00","assignment":"2023-06-02T12:08:11+02:00","program":null,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":4,"manager":99703,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[2325],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7595-99703-10","7595-105020-12"]},{"id":7308,"title":{"de":"CBmed: 2.22B - Next generation drug screening platform for precision oncology services ","en":"CBmed: 2.22B - Next generation drug screening platform for precision oncology services "},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2019-01-01T01:00:00+01:00","end_planned":"2023-12-31T01:00:00+01:00","end_effective":"2023-12-31T01:00:00+01:00","assignment":"2022-12-19T13:13:31+01:00","program":null,"subprogram":null,"organization":14080,"category":10,"type":10,"partner_function":4,"manager":56667,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7308-56667-10"]},{"id":7253,"title":{"de":"A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways","en":"A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways"},"short":"ONCOSCREEN","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2026-12-31T01:00:00+01:00","end_effective":"2026-12-31T01:00:00+01:00","assignment":"2022-11-16T10:41:30+01:00","program":219,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":2,"manager":99976,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":"101097036","ethics_committee":null,"edudract_number":null,"persons":["7253-99976-10","7253-100172-12","7253-108575-12","7253-119108-12","7253-133280-12"]},{"id":7215,"title":{"de":"Die Bedeutung von \"Glial Fibrillary Acidic Pretein\" im Plasma als diagnostischer und prognostischer Marker der Hirnalterung und der Alzheimer Krankheit","en":"The Role of Plasma Glial Fibrillary Acidic Protein as a diagnostic and prognostic marker in brain aging and Alzheimer´s disease"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2025-12-31T01:00:00+01:00","assignment":"2022-10-13T14:04:13+02:00","program":null,"subprogram":null,"organization":14051,"category":10,"type":10,"partner_function":4,"manager":57435,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[2269],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7215-57435-10","7215-73547-11"]},{"id":7288,"title":{"de":"Früherkennung von Bauchspeicheldrüsenkrebsg durch Liquid biopsies","en":"PANcreatic CAncer Initial Detection via liquid biopsy\r\n"},"short":"PANCAID","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2027-12-30T01:00:00+01:00","end_effective":"2027-12-31T01:00:00+01:00","assignment":"2022-12-05T10:24:50+01:00","program":219,"subprogram":null,"organization":14021,"category":10,"type":10,"partner_function":2,"manager":50899,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":"101096309","ethics_committee":null,"edudract_number":null,"persons":["7288-50899-10","7288-76215-12","7288-120331-12","7288-121409-12"]},{"id":7363,"title":{"de":"Digitale Zwillinge für die Behandlung von Vorhofflimmern","en":"Digital Twins to Treat Atrial Fibrillation"},"short":"DAWN-AF","url":null,"abstract":{"de":"Vorhofflimmern (VHF) ist die häufigste Arrhythmie des Herzens. Bei VHF handelt es sich um eine fortschreitende Erkrankung des Herzens. Je länger VHF andauert, umso schwieriger ist die Behandlung, und das Risiko Folgeschäden wie Schlaganfälle, Demenz oder Herzinsuffizienz zu erleiden nimmt zu. Die effektivste Therapie für VHF ist die Ablationstherapie mittels Herzkatheter, eine Prozedur, bei der Gewebe in den Vorhöfen des Herzens zerstört wird um die Ausbreitungspfade von elektrischen Wellen einzuschränken. Aktuelle Therapieformen sind generisch, die Variabilität der Patienten hinsichtlich der Struktur der Vorhöfe wird nicht berücksichtigt, weshalb VHF-Symptome auch nach anfänglich positiver Therapie häufig zurückkehren.\r\n\r\nDas Ziel des DAWN-AF Projektes ist es, einen personalisierten medizinischen Ansatz zu entwickeln, der auf Computermodellierung basiert. Konkret werden digitale Zwillinge der Vorhöfe des Herzens entwickelt. Diese können zur verbesserten Planung der VHF-Ablation im Computer verwendet werden, um ein Wiederauftreten von VHF zu verhindern. Dazu werden präoperative Messungen wie das Elektrokardiogramm und tomographische Bildgebung (MRT/CT) verwendet, um anatomisch und funktionell detaillierte digitale Zwillinge zu erstellen. Da diese Daten jedoch nicht ausreichen, um die Vorhöfe eindeutig zu charakterisieren, wird für jeden Patienten ein Satz an potenziellen digitalen Zwillingen erstellt, um dann für jede einzelne Variation die jeweils ideale Ablationsbehandlung zu bestimmen. Anhand von invasiven Messungen während des Eingriffs wird dann derjenige digitale Zwilling ausgewählt, der am besten zum Patienten passt. Eine wirtschaftliche Analyse der VHF-Therapie wird den Nutzen unseres mittels digitaler Zwillinge personalisierten Therapiezugangs bewerten. Dieser Nutzen ergibt sich aus einer frühzeitigen präventiven Behandlung, aus einem länger anhaltenden Therapieerfolg, aus einer verkürzten Eingriffsdauer und einer Reduktion des Eingriffsrisikos.\r\n","en":"Atrial Fibrillation (AF) is the most common cardiac arrhythmia. Since AF is progressive, the longer one has it, the harder it is to treat, and the risks of stroke, dementia and heart failure increase. The most effective treatment is catheter ablation therapy, a procedure that strategically destroys tissue to restrict propagation of electrical waves. However, approaches are currently generic, ignoring patient variability in atrial structure, and AF usually recurs. We aim to develop a personalised medicine approach based on computer modelling, to use digital twins to plan AF ablation to prevent recurrence. We propose to use preoperative measurements, imaging (MRI/CT) and the ECG, to build digital twins. However, these data are insufficient to uniquely characterize the atria, so we will build sets of potential digital twins for each patient, each of which will have its ideal ablation treatment determined. Invasive measurements acquired during the ablation procedure will be then used to select the digital twin that best matches the patient. Economic analysis will evaluate benefits arising from early preventative and longer-lasting treatment, reduced duration and procedural risks of interventions."},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-03-01T01:00:00+01:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2026-09-28T02:00:00+02:00","assignment":"2023-02-01T16:15:05+01:00","program":112,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":2,"manager":50966,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"I 6476-B","ethics_committee":null,"edudract_number":null,"persons":["7363-50966-10","7363-91352-12","7363-96212-12","7363-50967-12","7363-122514-12"]},{"id":8504,"title":{"de":"European Federation for Cancer Images","en":"European Federation for Cancer Images"},"short":"EUCAIM","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2024-07-01T02:00:00+02:00","end_planned":"2026-12-31T01:00:00+01:00","end_effective":"2026-12-31T01:00:00+01:00","assignment":"2024-11-19T14:02:04+01:00","program":null,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":1,"manager":99976,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["8504-99976-10","8504-133200-12","8504-133281-12"]},{"id":7191,"title":{"de":"ELPHI: ElektroPHoretische Implantate für steuerbare Chemotherapie von Gehirntumoren","en":"ELPHI: ElektroPHoretic Implants for Controlled Chemotherapy of Brain Tumors"},"short":"ELPHI","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2023-12-31T01:00:00+01:00","end_effective":"2024-03-31T01:00:00+01:00","assignment":"2022-09-29T18:00:07+02:00","program":null,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":4,"manager":99703,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7191-99703-10"]},{"id":7490,"title":{"de":"NR4A1 mediierte Regulation der Immuneevasion in Lymphomen","en":"NR4A1-mediated regulation of immune evasion in lymphoma*"},"short":"NIEL","url":null,"abstract":{"de":"Tumorzellen haben eine Reihe von Mechanismen entwickelt, um die immunvermittelte Erkennung und Zerstörung von Tumorzellen zu umgehen bzw. zu unterdrücken. Eine unserer Erkenntnisse ist, dass ein Teil der aggressiven B-Lymphome, maligne Tumore der antikörperproduzierenden Zellen, eine geringe Expression des Transkriptionsfaktors NR4A1 aufweisen. NR4A1 reguliert, wie andere Transkriptionsfaktoren, zahlreiche biologische Prozesse in Zellen. Die Funktion in aggressiven B-Lymphomen ist jedoch bis dato noch nicht untersucht worden. In unserer Vorstudie haben wir herausgefunden, dass eine niedrige NR4A1-Expression mit einer reduzierten Überlebensrate bei Standardtherapie einherging. In unserem Lymphommausmodell konnten wir nachweisen, dass der Verlust von Nr4a1 die Lymphomentwicklung deutlich beschleunigte, begleitet von einer erhöhten Expression immunsuppressiver Oberflächenmoleküle und einem höheren Gehalt an Immunzellen in Mäusen, die ein funktionierendes Immunsystem besaßen, aber nicht in Mausmodellen mit einem nicht funktionierenden Immunsystem. Weitere Analysen deuten darauf hin, dass der Verlust von Nr4a1 mit einer verminderten immunzellvermittelten Zerstörung von Lymphomzellen verbunden ist. Zusammenfassend deuten unsere Daten auf eine tumorsuppressive Funktion von NR4A1 hin, die durch immunregulatorische Eigenschaften bei der Entwicklung aggressiver Lymphome vermittelt wird.\r\nIn dem geplanten Projekt wollen wir mit globalen genetischen Ansätzen aufklären, welche Gene und/oder genetischen Programme durch NR4A1 reguliert werden, sowie mit Hilfe neuartiger Sequenzierungstechnologien die Auswirkungen von NR4A1 auf die Zusammensetzung und die Aktivität der Immunzellen in aggressiven Lymphomen untersuchen. Darüber hinaus wollen wir die Wirksamkeit von Immuntherapien als Einzelwirkstoffe sowie in Kombination (einschließlich neuer Moleküle) in Bezug auf die NR4A1-Expression bei aggressiven Lymphomen funktionell testen. Schließlich werden wir die Daten aus dem präklinischen Modell auf Patientenproben übertragen. Hier werden wir NR4A1, Antigenpräsentation und immunsuppressive Oberflächenmoleküle in unserer DLBCL-Patientenkohorte untersuchen, um unsere Erkenntnisse in einem klinischeren Umfeld zu validieren.\r\nAnhand der Ergebnisse könnten wir einen neuen Mechanismus identifizieren, der wesentlich zur Lymphomentwicklung beiträgt und zur Identifizierung von Lymphompatienten genutzt werden kann, die von einer neuartigen Immuntherapie profitieren könnten.\r\n","en":"Tumour cells have developed a number of mechanisms to avoid or suppress their recognition, targeting and killing by immune cells. We found out that a part of aggressive B cell lymphomas, a tumour consisting of the antibody-producing cells, exhibited low expression of the transcription factor NR4A1. NR4A1, like other transcription factors, regulates numerous biological processes in cells. However, its function has not been yet investigated in aggressive B cell lymphomas. In our preliminary study, we observed that low NR4A1 levelwas associated with reduced survival in patients treated with standard therapy. In mice with a functional immune system, we showed that loss of Nr4a1 markedly accelerated the development of lymphoma, with increased presence of surface molecules that inhibit immune cells, but also a higher content of these immune cells compared to immunodeficient mouse models. Further, our analyses indicate that loss of Nr4a1 is linked to reduced killing of lymphoma by immune cells. Taken together our data indicate a tumour-suppressive function of NR4A1 mediated by its immune regulatory properties in the development of aggressive lymphomas.\r\nIn the planned project, we aim to elucidate which genes and/or genetic programs are regulated by NR4A1 with global genetic approaches and to investigate the impact of NR4A1 on immune cell composition and activity in aggressive lymphomas using novel sequencing technologies. In addition, our aim is to functionally test the efficacy of immune therapies as single agents as well as in combination (including novel molecules) in relation to the NR4A1 level in aggressive lymphomas. Finally, we will transfer data from the preclinical model to patients samples and investigate NR4A1 expression, antigen presentation, and immune suppressive surface molecules in our DLBCL patient cohort  to validate our findings in a more clinical setting.\r\nBased on the finding, we might identify a novel mechanism, which significantly contribute to lymphoma development and which can be used to identify lymphoma patients who may benefit from a novel type of immune therapy. \r\n"},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-05-15T02:00:00+02:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2026-10-14T02:00:00+02:00","assignment":"2023-04-11T15:10:20+02:00","program":null,"subprogram":null,"organization":14082,"category":10,"type":10,"partner_function":4,"manager":59183,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"P36643","ethics_committee":null,"edudract_number":null,"persons":["7490-100134-12","7490-59183-10","7490-79614-12","7490-82501-12","7490-85928-12","7490-111069-12","7490-130555-12","7490-131900-12","7490-122350-12","7490-122590-12"]},{"id":7335,"title":{"de":"Entwicklung neuer Screeningverfahren von Anti-Aging Wirkstoffen in fluoreszierenden Fadenwürmern","en":"Development of new screening methods to analyze anti-aging compounds in fluorescent nematodes"},"short":"WormScreen","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2023-12-31T01:00:00+01:00","end_effective":"2023-12-31T01:00:00+01:00","assignment":"2023-01-17T13:50:34+01:00","program":null,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":85069,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[2471],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7335-85069-10"]},{"id":7661,"title":{"de":"XRes4HEALTH: Resilienztrainining mit eXtended reality für Menschen in Gesundheitsberufen","en":"XRes4HEALTH: eXtended reality enhanced resilience training for healthcare workers"},"short":"XRes4HEALTH","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-05-01T02:00:00+02:00","end_planned":"2024-06-30T02:00:00+02:00","end_effective":"2025-03-31T02:00:00+02:00","assignment":"2023-07-06T13:31:25+02:00","program":null,"subprogram":null,"organization":29444,"category":10,"type":10,"partner_function":1,"manager":79733,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[997],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7661-79733-10"]},{"id":7816,"title":{"de":"Untersuchung des Mechanismus' und der Rolle der mitochondrialen Dysfunktion im Dravetsyndrom","en":"Deciphering the mechanism and role of mitochondrial dysfunction in Dravet syndrome"},"short":"Mitoch Dysfkt_Dravetsyndrom","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-10-01T02:00:00+02:00","end_planned":"2024-12-31T01:00:00+01:00","end_effective":"2025-09-30T02:00:00+02:00","assignment":"2023-10-09T12:35:56+02:00","program":null,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":85069,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[1743],"funder_projectcode":"MEFO-94","ethics_committee":null,"edudract_number":null,"persons":["7816-85069-10"]},{"id":7309,"title":{"de":"Bewertung der Rolle der Succinat-Sensierung über GPR91 bei der T-Zell-vermittelten Anti-Tumor-Immunität ","en":"Evaluating the role of succinate sensing via GPR91 in T cell-mediated \r\nanti-tumour immunity "},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-03-01T01:00:00+01:00","end_planned":"2025-12-31T01:00:00+01:00","end_effective":"2026-09-30T02:00:00+02:00","assignment":"2022-12-20T13:44:44+01:00","program":null,"subprogram":null,"organization":14014,"category":10,"type":10,"partner_function":4,"manager":107391,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[2576],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7309-60706-12","7309-107391-10"]},{"id":7520,"title":{"de":"Isoformen der Pyruvatkinase als neue Biomarker und therapeutische Ziele bei Multipler Sklerose","en":"Pyruvate kinase isoforms as novel biomarkers\r\nand therapeutic targets in multiple sclerosis\r\n"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-05-01T02:00:00+02:00","end_planned":"2023-12-31T01:00:00+01:00","end_effective":"2024-04-30T02:00:00+02:00","assignment":"2023-04-19T16:13:39+02:00","program":null,"subprogram":null,"organization":14014,"category":10,"type":10,"partner_function":4,"manager":107391,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[2471],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7520-57435-12","7520-107391-10"]},{"id":7497,"title":{"de":"Elektronisches Smart-Patch System zur kabellosen Übertragung von molekularen Biomarkern für Gesundheit und Wohlbefinden","en":"Electronic smart patch system for wireless monitoring of molecular biomarkers for healthcare and well-being"},"short":"ELSAH","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2023-01-01T01:00:00+01:00","begin_effective":"2023-01-01T01:00:00+01:00","end_planned":"2023-12-31T01:00:00+01:00","end_effective":"2023-12-31T01:00:00+01:00","assignment":"2023-04-12T16:51:00+02:00","program":214,"subprogram":null,"organization":14080,"category":10,"type":10,"partner_function":2,"manager":50877,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[10],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["7497-50877-10"]}]}